Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men - A randomized multicenter study

Urology

Volumn 83, Issue 2, 2014, Pages 416-421

  Lin, Victor Chia Hsiang ^a   Liao, Chun Hou ^b   Kuo, Hann Chorng ^c  

^a I SHOU UNIVERSITY   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; AGED; AZASTEROIDS; DISEASE PROGRESSION; DOXAZOSIN; DRUG THERAPY, COMBINATION; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; TIME FACTORS;

EID: 84895069783     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.09.036     Document Type: Article

References (13)

1. S.J. Jacobsen, C.J. Girman, and M.M. Lieber Natural history of benign prostatic hyperplasia Urology 58 2001 5 16
2. M. Emberton, J.M. Fitzpratick, and M. Garcia-Losa et al. Progression of benign prostatic hyperplasia: systemic review of the placebo arms of clinical trials BJU Int 102 2008 981 986
3. M. Emberton, E.B. Cornel, and P.F. Bassi et al. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management Int J Clin Pract 62 2008 Jul 1076 1086
4. S. Gravas, and M. Oelke Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH World J Urol 28 2010 Feb 9 15
5. J.D. McConnell, C.G. Roehrborn, and O.M. Bautista et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 349 2003 2387 2398
6. C.G. Roehrborn, P. Siami, and J. Barkin et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study J Urol 179 2008 616 621
7. C.G. Roehrborn, P. Siami, and J. Barkin et al. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from CombAT study Eur Urol 55 2009 461 471
8. C.G. Roehrborn, P. Siami, and J. Barkin et al. The effect of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study Eur Urol 57 2010 123 131
9. J. Barkin, M. Guimarães, and G. Jacobi et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride Eur Urol 44 2003 Oct 461 466
10. J.C. Nickel, J. Barkin, and C. Koch et al. Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers Can Urol Assoc J 2 2008 Feb 16 21
11. M.M. Issa, P.J. Lin, and M.T. Eaddy et al. Comparative analysis of alpha-blocker utilization in combination with 5-alpha reductase inhibitors for enlarged prostate in a managed care setting among Medicare-aged men Am J Manag Care 14 5 Suppl 2 2008 May S160 S166
12. Y.M. Liaw, and H.C. Kuo Discontinuation of an alpha-1 blocker or 5-alpha-reductase inhibitor after combination medical treatment in patients with benign prostatic hyperplasia Tzu Chi Med J 18 2006 91 96
13. Y.B. Jeong, K.S. Kwon, and S.D. Kim et al. Effect of discontinuation of 5alpha-reductase inhibitors on prostate volume and symptoms in men with BPH: a prospective study Urology 73 2009 Apr 802 806